Azione 6L7A BELLEROPHON THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Bellerophon Therapeutics, Inc. Börse Stuttgart

Azioni

6L7A

US0787713009

Mercato chiuso - Börse Stuttgart
Altri mercati azionari
 08:01:13 13/10/2023 		Variaz. 5gg Var. 1 gen.
0,421 EUR +20,98% Grafico intraday di Bellerophon Therapeutics, Inc. +26,05% -45,08%
04/03 Bellerophon Therapeutics, Inc. annuncia le dimissioni di Mary Ann Cloyd e Scott Bruder da membri del Consiglio di amministrazione CI
2023 Bellerophon Therapeutics, Inc. annuncia cambiamenti esecutivi CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
North American Morning Briefing : Stock Futures -2-
North American Morning Briefing : More Tech -2-
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
North American Morning Briefing : Focus Turns to -2-
North American Morning Briefing : Stocks Set for -2-
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors
Bellerophon Therapeutics, Inc. Announces Executive Changes
Bellerophon Therapeutics, Inc. Announces Executive Changes
North American Morning Briefing : Stocks Futures Steady on Rates Optimism
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from S&P TMI Index
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board
Bellerophon Therapeutics, Inc.(OTCPK:BLPH) dropped from NASDAQ Composite Index
North American Morning Briefing : Focus Shifts to -2-
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director
Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione BLPH
  4. Azione 6L7A
  5. Notizie Bellerophon Therapeutics, Inc.
  6. Altre lingue